title: State-of-the-art classification and multimodality treatment of malignant thymoma.
abstract: Thymomas are the most common tumors of the anterior mediastinum. Classification, treatment options and understanding of the pathophysiology of thymoma have changed over the past years. It is hoped that novel therapeutic strategies will lead to a survival benefit in these patients. It has turned out that patients with thymoma are best treated with multimodality therapy. In this review, a pathologist, an immunologist, a surgeon, a radiotherapist, a pneumologist and oncologists discuss the current status of classification and strategies for the treatment of thymoma patients.
authors.affiliation: Medizinische Klinik und Poliklinik III, Rheinische Friedrich-Wilhelms-Universität, Sigmund-Freud-Str. 25, 53105 Bonn, Germany. hkoppitz@uni-bonn.de
authors.forename: Hannah
authors.initials: H
authors.lastname: Koppitz
authors.forename: Jürgen K
authors.initials: JK
authors.lastname: Rockstroh
authors.forename: Heinrich
authors.initials: H
authors.lastname: Schüller
authors.forename: Jens
authors.initials: J
authors.lastname: Standop
authors.forename: Dirk
authors.initials: D
authors.lastname: Skowasch
authors.forename: Hans Konrad
authors.initials: HK
authors.lastname: Müller-Hermelink
authors.forename: Ingo G H
authors.initials: IG
authors.lastname: Schmidt-Wolf
mesh_terms: D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D006801:Humans; D020360:Neoadjuvant Therapy; D013945:Thymoma / Q000145:classification* / Q000453:epidemiology / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D013953:Thymus Neoplasms / Q000145:classification* / Q000453:epidemiology / Q000209:etiology / Q000473:pathology / Q000628:therapy*